ScreenerHero

EIKN Eikon Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · eikontx.com
7.295USD-3.25%Mkt Cap: 408.40M $P/E: —

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$58.08BUSDP/E 35.4
ARGX
argenx SE
$48.23BUSDP/E 31.4
RVMD
Revolution Medicines, Inc.
$43.05BUSD
UCB
UCB SA
$41.82BUSDP/E 17.8
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap408.40M USD
Enterprise Value127.82M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-324.25M USD
Revenue/Share—
Last Price7.295 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees384
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.19
PEG—
EV/EBITDA-0.40
EV/Revenue—
P/S—
P/B0.87
EPS (TTM)-8.51
EPS (Forward)-6.33
52W Range
7.0153% of range17.40
52W High17.40 USD
52W Low7.015 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE36.89%
ROA-54.52%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-188.52M USD
CapEx (TTM)46.74M USD
FCF Margin—
FCF Yield—
Net Debt-278.96M USD
Net Debt/EBITDA0.88
Balance Sheet
Debt/Equity-0.29
Current Ratio9.89
Quick Ratio9.61
Book Value/Sh8.62 USD
Cash/Share9.81 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)24.60 USD
Upside (mean)+237.2%
Target Range4.000 USD – 32.00 USD
4.000+237.2% to mean32.00
# Analysts5
Ownership
Shares Out.54.17M
Float32.49M
Insiders17.38%
Institutions69.59%
Short Interest
Short Ratio9.8d
Short % Float13.37%
Short % Out.10.07%
Shares Short5.45M
Short (prev mo.)4.18M
Technical
SMA 509.750 (-25.2%)
SMA 20010.82 (-32.6%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)606.82K
Avg Vol (10d)513.10K
Technical Indicators
RSI (14)35.2
MACD-0.7154
MACD Signal-0.6748
MACD Hist.-0.0406
BB Upper9.706 USD
BB Middle8.320 USD
BB Lower6.934 USD
BB Width33.32%
ATR (14)0.6810 USD
Vol Ratio (20d)1.29x